Isma Benattia named Wyeth Consumer Healthcare head of global R&D
MADISON, N.J. Wyeth Consumer Healthcare announced that Isma Benattia has been named executive vice president of Global Research and Development, effective immediately.
In her new role, Benattia will be in charge of bringing new products to market and managing regulatory necessities regarding Wyeth’s over-the-counter products.
Benattia has served at Wyeth Pharmaceuticals since 2003, where she most recently was vice president in charge of Global Labeling. She previously held the position of executive medical director of neuroscience, where she played a leading role in managing scientific and regulatory issues involving Effexor, Wyeth’s second largest brand in terms of global revenue.
Prior to joining Wyeth, Benattia led global clinical programs for major products at Pfizer and Eli Lilly. She holds Master’s degrees in Pharmacology and Psychotropic Drugs; Methodology of Clinical Research and Medical and Marketing Management.
Church and Dwight introduces First Response digital display early result pregnancy test
PRINCETON, N.J. The new First Response Gold Early Result Digital Pregnancy Test features an easy-to-read digital display that tells a woman “Yes” or “No”. Potentially pregnant couples no longer have to wonder if they see a blue line or a pink line or two lines or none at all. In addition, the Early Result Digital Pregnancy Test is the first First Response pregnancy test to feature an electronic “ready to use” indicator, which confirms the test is ready for use.
“A clear ‘yes’ or ‘no’ response is sure to be a relief for women who are eager to find out if they are pregnant,” said Lisa Masterson, a Santa Monica-based OB/GYN affiliated with Cedars-Sinai, St. John’s and UCLA/Santa Monica hospitals. “The indicator showing that the test is working relieves anxiety for women; letting them know an accurate answer is coming soon.”
Unlike other digital tests on the market, First Response stated, the Early Result Digital Pregnancy Test uses a proprietary gold technology detects two different forms of human chorionic gonadotropin, the pregnancy hormone, including the variant hormone that better predicts early pregnancy. The sensitivity of First Response technology makes it possible to detect the presence of just 18 mlU of hCG in urine. And, as with its proven Early Result Pregnancy Test, the Early Result Digital Pregnancy Test detects hCG up to five days before a woman’s missed period.
The test is more than 99 percent accurate from the day of a woman’s expected period at detecting typical pregnancy hormone levels, the company stated.
The Food and Drug Administration approved the First Response Gold Early Result Digital Pregnancy Test in May 2007 and it will be available on drugstore shelves later this year.
Perrigo announces FDA approval for generic Prilosec
ALLEGAN, Mich. Perrigo on Tuesday added a private-label version of Johnson & Johnson’s Pepcid Complete to its gastrointestinal portfolio, which will include the launch of a store brand Prilosec OTC in the next quarter, with the announcement that the Food and Drug Administration approved its application for over-the-counter famotidine 10 mg, calcium carbonate 800 mg and magnesium hydroxide 165 mg, chewable tablets.
Annual retail sales for Pepcid Complete chewable tablets are estimated to be approximately $95 million, Perrigo reported.
“This final approval reflects our continuing investment in new products,” Perrigo’s Chairman and chief executive officer Joseph Papa stated. “As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders.”